Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly misses third-quarter profit amid soaring demand for weight-loss drug
06:54am, Wednesday, 30'th Oct 2024
Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related costs.
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
06:45am, Wednesday, 30'th Oct 2024
Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zypr
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
04:45am, Wednesday, 30'th Oct 2024
Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth.
Is Eli Lilly Stock a Buy?
04:40am, Wednesday, 30'th Oct 2024
Eli Lilly has been a huge winner with its GLP-1 drugs.
Eli Lilly Reports Earnings Wednesday. It's All About Zepbound.
04:30pm, Tuesday, 29'th Oct 2024
Shares are up more than 50% already this year, as the story surrounding the company's GLP-1 drugs gets better and better.
Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?
04:00pm, Tuesday, 29'th Oct 2024
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines, Mounjaro and Zepbound.
Gradual dosing of Lilly Alzheimer's drug cuts brain-swelling risk, study finds
12:19pm, Tuesday, 29'th Oct 2024
Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients experiencing potentially serious brain swelling, according to interim results of a lat
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
12:15pm, Tuesday, 29'th Oct 2024
A change in the initiation of donanemab dosing, shifting one vial of donanemab from the first infusion to the third infusion, lowered ARIA-E to 14% compared to 24% in patients receiving the standard d
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains
12:04pm, Tuesday, 29'th Oct 2024
Eli Lilly and Co LLY will be reporting its third-quarter earnings on Wednesday. Wall Street expects $1.45 in EPS and $12.10 billion in revenues as the company reports at 10 a.m.
6 Stocks Dominate Market's 'Best 6 Months' — Starting This Week
08:00am, Tuesday, 29'th Oct 2024
If you had to choose the best time to invest in the S&P 500 — it's the six months starting in November.
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
07:05am, Tuesday, 29'th Oct 2024
One key disease-prevention market is drawing closer to being within reach.
Eli Lilly's Latest Setback Could Portend an Unexpected Headwind for the Stock
06:30am, Tuesday, 29'th Oct 2024
The odds of its new drug getting established in the U.K. are now much lower.
What You Need To Know Ahead of Eli Lilly Earnings
05:15pm, Monday, 28'th Oct 2024
As pharmaceutical giant Eli Lilly (LLY) plans to report third-quarter earnings Wednesday morning, analysts are focused on the production and sales of Mounjaro and Zepbound—two popular weight-loss dr
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
01:36pm, Monday, 28'th Oct 2024
Eli Lilly stock (NYSE: LLY) will report its Q3 results on Wednesday, October 30. The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the
Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?
01:10pm, Monday, 28'th Oct 2024
Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.
